+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Effect of prostaglandin d 2 in modulation histamine release from human basophils

Journal of Pharmacology & Experimental Therapeutics 228(2): 400-406

Effect of prostaglandin d 2 in modulation histamine release from human basophils

Prostaglandin (PG) D2 is the major cyclooxygenase metabolite of arachidonic acid released after immunologic stimulation of mast cells. This PG is unlike other PG previously investigated in that it enhances human basophil histamine release at concentrations of 1-100 nM. Enhancement is seen when antigen, the phorbol diester, 12-0-tetradecanoylphorbol-13-acetate and ionophore A23187 [calcimycin] are used to initiate release and, in preparations of basophils, purified to 51-66% of total cell number as well as in preparations of mixed leukocytes. This enhancement is a late or second stage phenomenon as defined by the 2 stages of histamine release and is additive with the enhancement produced by D2O, but not with the enhancement produced by indomethacin or 5-hydroperoxyeicosatetraenoic acid. PGD2 also reverses the inhibition of release produced by drugs and hormones such as dimaprit and PGE2 that activate adenylate cyclase to increase cellular cAMP levels. PGD2 may play an important role in allergic and immunologic reactions and a mechanism by which mast cells and basophils can interact during these reactions is suggested.

(PDF 0-2 workdays service: $29.90)

Accession: 005264772

PMID: 6198512

Related references

Adenosine receptor on human basophils: modulation of histamine release. Journal of Immunology 123(4): 1473-1477, 1979

Comparison of histamine release and prostaglandin E2 production of human basophils in atopic and normal individuals. Archives of Dermatological Research 279(8): 536-542, 1987

Modulation of histamine release from human basophils in vitro by physiological concentrations of zinc. Journal of Pharmacology and Experimental Therapeutics 217(2): 292-298, 1981

Modulation of histamine release from rat mast cells and human basophils by serum factors. Federation Proceedings 39(3): ABSTRACT 2238, 1980

Modulation of the release of histamine and arachidonic acid metabolites from human basophils and mast cells by auranofin. Agents and Actions 18(1-2): 100-102, 1986

The effect of bacterial lipopolysaccharide (LPS) on histamine release from human basophils. I. Enhancement of immunologic release by LPS. Clinical Immunology and Immunopathology 34(3): 355-365, 1985

Modulation of the effect of histamine-releasing lymphokine on human basophils. Agents and Actions 14(3-4): 501-505, 1984

Effect of batrachotoxin on histamine release hr from human basophils. Journal of Allergy & Clinical Immunology 87(1 PART 2): 156, 1991

Complement induced histamine release from human basophils part 2 mechanism of the histamine release reaction. Journal of Immunology 116(3): 639-646, 1976

In vitro inhibition, by loratadine and descarboxyethoxyloratadine, of histamine release from human basophils, and of histamine release and intracellular calcium fluxes in rat basophilic leukemia cells (RBL-2H3). Biochemical Pharmacology 47(5): 789-794, 1994